Індекс рубрикатора НБУВ: Р569.696.2

Рубрики:

Пухлини передміхурової залози

Шифр НБУВ: Ж14160 Пошук видання у каталогах НБУВ 

Індекс рубрикатора НБУВ: Р56-52 + Р281.82-2

Рубрики:

Онкологія

Засоби, які застосовують для лікування новоутворень. Протипухлинні засоби

Шифр НБУВ: Ж14160 Пошук видання у каталогах НБУВ 

Aim - the genetic mechanisms of resistance to chemotherapy in B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL) are not clear. We aimed to determine the peculiarities of abnormal karyotype formation in bone marrow (BM) cells and peripheral blood (PB) blast transformed B-cells in relapse of B-CLL/SLL. Cytogenetic GTG banding technique and molecular cytogenetic in interphase cells (i-FISH) studies of BM cells and PB blast transformed B-lymphocytes were performed in 14 patients (10 males and 4 females) with B-CLL/SLL. The results of karyotyping BM and PB cells revealed the heterogeneity of cytogenetic abnormalities in combined single nosological group of B-CLL/SLL. In PB B-cells, chromosome abnormalities related to a poor prognosis group were registered 2,5 times more often than in BM cells. Additional near tetraploid clones that occurred in 57,1 % cases were the peculiar feature of BM cell karyotypes. Chromosomal rearrangements characteristic of the group of adverse cytogenetic prognosis were revealed in all cases from which in 2 cases by karyotyping BM cells, in 6 cases in PB B-cells and in 8 cases by the i-FISH method in BM cells, i.e. their detection frequency was 3 times higher in PB B-cells and 4 times higher when analyzing by i-FISH in BM cells. Conclusions: mismatch in abnormal karyotypes in BM and PB B-cells by the presence of quantitative and structural chromosomal rearrangements may be indicative of simultaneous and independent processes of abnormal clone formation in the lymph nodes and BM hematopoietic cells. Accumulation the information about previously unidentified chromosomal rearrangements in relapse of the disease may help to understand the ways of resistance formation to chemotherapy.

Індекс рубрикатора НБУВ: Р413.201.1 + Р569.433.2

Рубрики:

Гастрити. Дуоденіти

Пухлини шлунку і дванадцятипалої кишки

Шифр НБУВ: Ж14160 Пошук видання у каталогах НБУВ 

Індекс рубрикатора НБУВ: Р569.423

Рубрики:

Пухлини легенів

Шифр НБУВ: Ж14160 Пошук видання у каталогах НБУВ 

Індекс рубрикатора НБУВ: Р569.133.1

Рубрики:

Пухлини молочних (грудних) залоз

Шифр НБУВ: Ж14160 Пошук видання у каталогах НБУВ 

Індекс рубрикатора НБУВ: Р281.82 + Р56-522

Рубрики:

Засоби, які застосовують для лікування новоутворень. Протипухлинні засоби

Онкологія

Шифр НБУВ: Ж14160 Пошук видання у каталогах НБУВ 

Індекс рубрикатора НБУВ: Р569.435.2-5

Рубрики:

Пухлини жовчного міхура і жовчовивідних шляхів

Шифр НБУВ: Ж14160 Пошук видання у каталогах НБУВ 

Індекс рубрикатора НБУВ: Р353.4

Рубрики:

Тканинна терапія. Клітинна терапія

Шифр НБУВ: Ж14160 Пошук видання у каталогах НБУВ 

Significant progress in the promotion of procedural technologies associated with the transplantation of hematopoietic stem cells caused a rapid increase in activity. The exchange of hematopoietic stem cells for unrelated donor transplantations is now much easier due to the relevant international professional structures and organizations established to support cooperation and standard setting, as well as rules for the functioning of both national donor registries and cord blood banks. These processes are increasing every year and are contributing to the outpacing rates of development in this area. Products within their country should be regulated by the competent government authorities. This study analyzes the work of international and national levels of support for transplantation activity in the field of unrelated hematopoietic stem cell transplantation, the standardization order of technologies, as well as data that justify the need to create a network of donated umbilical cord blood banks in Ukraine as a factor in the development of allogeneic transplantation. This will promote the accessibility of international standards for the treatment of serious diseases for Ukrainian citizens.

Індекс рубрикатора НБУВ: Р353.4

Рубрики:

Тканинна терапія. Клітинна терапія

Шифр НБУВ: Ж14160 Пошук видання у каталогах НБУВ 

About 1 % of women suffer from premature ovarian failure, which leads to a significant deterioration in the life quality. Most often this condition is caused by performed chemotherapy, autoimmune diseases, surgery performed on ovaries, uterus, or fallopian tubes. The aim of this study was to compare different approaches of tissue and cell therapy in restoring the sexual function in case of ovarian failure induced by chemotherapy. The study was carried out in BALB/c mice with the modeled ovarian failure, induced by cyclophosphamide and busulfan. The restoration dynamics of ovarian and sexual function, liver and kidneys after application of cryopreserved explants, cryoextract, placental mesenchymal stem cells, those of adipose tissue has been studied. It has been shown that the use of various methods of cell and tissue therapy has comparable efficacy when treating an ovarian failure induced by chemotherapy. The most rapid and complete restoration of the reproductive system, liver and kidneys was observed when using the placental explants, extract and cells, but not with the use of mesenchymal stem cells of adipose tissue. No recovery of fertility in this experiment was observed. Conclusion: various methods of cellular and tissue therapy are perspective in treatment of the chemotherapy complications. More effective are placental derivates.

Background: imatinib is tyrosine kinase inhibitor (TKI) and as a targeted anti-cancer agent has significantly changed chronic myeloid leukemia (CML) prognosis and patient survival. Currently TKI is the main therapy in CML Philadelphia chromosome-positive (Ph-positive) cases. When generics of imatinib appeared in the pharmaceuticals market, reimbursement policies in many countries switched to using generics or encouraged use of generic imatinib to lower the expenses. Cost savings were substantial; however, for doctors and CML patients the efficacy, safety and quality of generic imatinib were an issue of concern. Objective: since the global number of CML patients, who in the future will have to switch from original imatinib to generic imatinib, is high, the aim of study was to monitor, whether during 24 months of generic imatinib usage patients maintain the achieved major molecular response (MMR) or whether the treatment results are inferior. We conducted a retrospective study, which included CML patients, who were above 18 years of age and who until May 2013 had used at least for 2 years (24 months) the original imatinib, and following that used at least for 24 months one of the generic imatinib medicines. In 2013, before switching to generic imatinib, all patients had reached MMR in accordance with European LeukemiaNet (ELN) Guidelines. Every three months blood count, BCR-ABL fusion gene (BCR-ABL), biochemical analysis and side effect were monitored. Our study proved that CML patients, who had achieved MMR by original imatinib therapy, retained MMR during 24 months of generic imatinib therapy. Nobody was switched to second line generation TKI. During observation period neither haematological, nor non-hematological toxicity was found. Conclusion: our study proved that CML patients, who had achieved MMR by original imatinib therapy, retained MMR during 24 months of generic imatinib therapy. This demonstrates that generic imatinib is not inferior to original imatinib. As to expenses, the annual costs of generic imatinib are lower by 96 %, which is a significant benefit to health-care financing.

Індекс рубрикатора НБУВ: Р569.133.1

Рубрики:

Пухлини молочних (грудних) залоз

Шифр НБУВ: Ж14160 Пошук видання у каталогах НБУВ 

Індекс рубрикатора НБУВ: Р56 я431

Рубрики:

Онкологія

Шифр НБУВ: Ж14160 Пошук видання у каталогах НБУВ 

Aim - classic activating mutations L858R and deletions in exon 19 (19del) in the gene for epidermal growth factor receptor (EGFR) are associated with sensitivity of the non-small cell lung cancer (NSCLC) to therapy with tyrosine kinase inhibitors (TKI). Insertions in EGFR exon 19 (19ins) are rare mutations in NSCLC; response of cases with 19ins to TKI is not well studied. Here we report a case of NSCLC with 19ins in a Russian patient who was treated with gefitinib. We also overview cases of 19ins reported in the literature. Case description: a 48 years old female Russian patient was diagnosed with adenocarcinoma of the lung (T3N2M1, stage IV). Mutation 19ins was detected in the tumor biopsy by fragment analysis and genotyped by Sanger sequencing as p.I744_K745insKIPVAI. Treatment with gefitinib (250 mg/dav) resulted in clinical and radiological improvements scored as partial response that lasted 12 months. Conclusion: treatment with gefitinib of lung adenocarcinoma that carries mutation EGFR 19ins can result in durable response.

Numerous experimental studies have demonstrated anticancer action of polyphenolic plant metabolites. However, data about associations between dietary intake of plant-derived flavonoids and prostate cancer risk are still sparse and inconsistent. This minireview compiles the epidemiological findings published to date on the role of flavonoids in prostate tumorigenesis, discusses the reasons of inconsistencies and elicits the promising results for chemoprevention of this malignancy. Long-term consumption of high doses of soy isoflavones can be the reason of markedly lower clinically detectable prostate cancer incidence among Asian men compared to their counterparts in the Western world. The ability to metabolize daidzein to equol, the most biologically active isoflavone, by the certain intestinal bacteria also seems to contribute to this important health benefit. The increasing incidence rate of prostate cancer related to adoption of westernized lifestyle and dietary habits makes the issue of chemoprevention ever more important and directs the eyes to specific food components in the Eastern diet. If further large-scale epidemiological studies will confirm the protective effects of isoflavones against prostate cancer, this could provide an important way for prostate cancer prevention, as diet is a potentially modifiable factor in our behavioral pattern.

The aim of this study was to characterize the proliferative activity of the anti-histone HI IgGs towards human T-leukaemia CEM cells. Anti-histone HI IgGs were purified from blood serum of systemic lupus erythematosus patients by precipitation of serum proteins with 50 % ammonium sulfate followed by a sequential affinity chromatography on Protein G-Sepharose and histone H1-Sepharose columns. To avoid contamination with other proteins, anti-histone H1 IgGs were subjected to strongly acidic pH 2,0 during gel filtration through HPLC column. The effects of the anti-histone HI IgGs on cell viability and cell cycle were tested by MTS-assay and flow cytometry, correspondingly. The cross-reactivity of the anti-histone H1 antibodies towards heterogenetic and cellular antigens was evaluated by Western-blot analysis. It was found that incubation of CEM cells with the HPLC-purified anti-histone H1 IgGs resulted in significant stimulation of cell growth by 46 % after 48 h of incubation. These IgGs possess an antigenic poly-specificity to positively charged heterogenetic antigens and different cellular antigens. FITC-labeled and biotinylated anti-histone H1 IgGs are internalized by CEM cells and preferentially accumulated in the cytoplasm. Conclusion: the anti-histone H1 IgGs are shown to internalize human T-leukemia CEM and stimulate their proliferation. These IgGs are polyspecific toward cellular antigens.

In acute myeloid leukemia (AML)the functional abnormalities of osteopontin (OPN), NF-kB, PI3K/AKT/mTOR/PTEN pathway or beta-catenin have been considered. Aim - to analyze the response of U937 cells to parthenolide (PTL) through the involvement of expression of OPN protein, Relit. AKT1, mTOR, PTEN and beta-catenin genes. The U937 cells were treated with PTL at concentrations of 4 mu M (IC25) or 6 mu M (IC50) and with OPN siRNA for MTT assay and colony forming assay. Western blot analysis using antibodies against OPN was performed with lysates of PTL-treated cells. Quantitative real-time polymerase chain reaction was performed using primers for OPN siRNA, RelB, AKT1, mTOR, PTEN and beta-catenin. PTL reduces OPN protein level and down-regulates RelB mRNA in U937 cell line. Suppression of OPN with siRNA increases the cytotoxic effects of PTL. Also, mRNA expression of AKT1, mTOR, PTEN, and beta-catenin decreases with PTL or OiW siRNA. Conclusion: sensitivity of U937 cells to PTL can be associated with the reduction in expression of prosurvival mediators.

Індекс рубрикатора НБУВ: Р569.68

Рубрики:

Пухлини ЛОРорганів (онкооторинолярингологія)

Шифр НБУВ: Ж14160 Пошук видання у каталогах НБУВ